Mark R. Waddle

Mark R. Waddle

Auto-generated profile, based on publicly available information

Mark R. Waddle

Department of Radiation Oncology, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2018 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
JMJackson M. May
Jackson M. May
MWMark R. Waddle
Mark R. Waddle
DMDaniel H. Miller
Daniel H. Miller
WSWilliam Stross
William Stross
TKTasneem A. Kaleem
Tasneem A. Kaleem
JPJennifer L. Peterson
Jennifer L. Peterson
Histiocytic sarcoma (HS) is an aggressive malignant neoplasm. HS in the central nervous system is exceptionally rare and associated with a poor prognosis. This report documents a case of primary HS of the central nervous system with treatment including surgery, radiotherapy, and chemotherapy. Our patient was a 47 year old female presenting with progressive ataxia, headaches, imbalance, nausea, vomiting, and diplopia. MRI showed a heterogeneously enhancing lesion approximately 2.9 × 3.0 × 2.3 cm centered upon the cerebellar vermis with mild surrounding vasogenic edema and abnormal enhancement of multiple cranial nerves. The patient underwent surgical debulking, which revealed histiocytic sarcoma with grossly purulent drainage. Staging revealed diffuse leptomeningeal involvement, primarily involving the brain and lower thoracic and lumbar spine. She underwent adjuvant radiotherapy to the brain and lower spine and was started on high dose methotrexate. However, she experienced progressive disease in the cervical and thoracic spine as well as pulmonary involvement. Genomic sequencing of her tumor showed a mutation in the platelet-derived growth factor receptor A (p.V0681) which could be targeted with Dasatinib. However, she did not tolerate Dasatinib and she succumbed to progressive disseminated disease eight months from original diagnosis. Our pathologic evaluation also revealed expression of PD-L1 and PD-L2 by tumor cells raising the potential therapeutic role for immune checkpoint inhibition. This case provides an example of effective CNS control with resection and moderate doses of radiation therapy. A review of the literature confirms aggressive multidisciplinary treatment is the most effective treatment against this disease. In addition, genomic sequencing may play an important role in determining new therapeutic options. However, CNS histiocytic sarcoma remains an aggressive disease with a propensity for early widespread dissemination and few long term survivors.

5 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EJElizabeth B. Jeans
Elizabeth B. Jeans
Daniel K. EbnerDaniel K. Ebner
Daniel K. Ebner
HTHirotoshi Takiyama
Hirotoshi Takiyama
KQKaitlin Qualls
Kaitlin Qualls
DCDanielle A. Cunningham
Danielle A. Cunningham
MHMichael G Haddock
Michael G Haddock
No standard treatment paradigm exists for previously irradiated locally recurrent rectal cancer (PILRRC). Carbon-ion radiotherapy (CIRT) may improve oncologic outcomes and reduce toxicity compared with combined modality therapy (CMT). Eighty-five patients treated at Institution A with CIRT alone (70.4 Gy/16 fx) and eighty-six at Institution B with CMT (30 Gy/15 fx chemoradiation, resection, intraoperative electron radiotherapy (IOERT)) between 2006 and 2019 were retrospectively compared. Overall survival (OS), pelvic re-recurrence (PR), distant metastasis (DM), or any disease progression (DP) were analyzed with the Kaplan–Meier model, with outcomes compared using the Cox proportional hazards model. Acute and late toxicities were compared, as was the 2-year cost. The median time to follow-up or death was 6.5 years. Median OS in the CIRT and CMT cohorts were 4.5 and 2.6 years, respectively (p ≤ 0.01). No difference was seen in the cumulative incidence of PR (p = 0.17), DM (p = 0.39), or DP (p = 0.19). Lower acute grade ≥ 2 skin and GI/GU toxicity and lower late grade ≥ 2 GU toxicities were associated with CIRT. Higher 2-year cumulative costs were associated with CMT. Oncologic outcomes were similar for patients treated with CIRT or CMT, although patient morbidity and cost were lower with CIRT, and CIRT was associated with longer OS. Prospective comparative studies are needed.

27 July 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
KCKiran Chauhan
Kiran Chauhan
DEDaniel K. Ebner
Daniel K. Ebner
KTKatherine Tzou
Katherine Tzou
KRKaren Ryan
Karen Ryan
JMJackson May
Jackson May
MWMark R. Waddle
Mark R. Waddle
Prostate cancer patients undergoing external beam radiation therapy (EBRT) benefit from a full bladder to decrease bowel and bladder toxicity. Ultrasound may offer a proxy metric for evaluation, sparing CBCT dosing. Patients were prospectively enrolled pre-simulation from January 2017 to February 2018. Bladder volume was evaluated prior to RT using US daily and CBCT for three daily treatments and then weekly unless otherwise indicated. 29 patients completed median 40 days of RT, resulting in 478 CBCT and 1,099 US bladder volumes. 21 patients were treated to intact glands and 8 to the post-prostatectomy bed. Median patient age was 70 years. Bladder volume on CBCT and US positively correlated (r = 0.85), with average bladder volume for all patients of 162 mL versus 149 mL, respectively. Bladder volume during treatment was consistently lower than the volume at CT simulation (153 mL vs 194 mL, p<0.01) and progressively declined during treatment. Patients older than 70 years presented with lower average bladder volumes than those < 70 years (122 mL vs 208 mL, respectively, p<0.01). Patients with the highest agreement between CBCT and US (<10% variability) had higher average bladder volumes (192 mL vs 120 mL, p=0.01). US was found to be an accurate measure of bladder volume and may be used to monitor daily bladder volumes in patients being treated with radiation for prostate cancer.

7 September 2022 in Cancer
Verified
Journal Article
Closed access
RKRoman Oleksander Kowalchuk
Roman Oleksander Kowalchuk
HKHayeon Kim
Hayeon Kim
WHWilliam S. Harmsen
William S. Harmsen
EJElizabeth B. Jeans
Elizabeth B. Jeans
LMLindsay K. Morris
Lindsay K. Morris
MWMark R. Waddle
Mark R. Waddle

26 December 2022 in Cancer
Verified
Journal Article
Closed access
RKRoman Oleksander Kowalchuk
Roman Oleksander Kowalchuk
TMTrey C. Mullikin
Trey C. Mullikin
MFMarcus Florez
Marcus Florez
BDBrian S. De
Brian S. De
GSGrant M. Spears
Grant M. Spears
KMKenneth W. Merrell
Kenneth W. Merrell

16 March 2021 in JMIR Cancer
Verified
Journal Article
Open access
SOSven P Oman
Sven P Oman
HZHimesh Zaver
Himesh Zaver
MWMark Waddle
Mark Waddle
JCJuan E Corral
Juan E Corral
Background: Pancreatic cysts are a complex medical problem with several treatment options. Patients use web-based health information to understand their conditions and to guide treatment choices. Objective: The goal of this study was to describe the quality and readability of publicly available web-based information on pancreatic cysts and to compare this information across website affiliations. Methods: A Google search for “pancreatic cysts” was performed and the first 30 websites were evaluated. Website affiliations were classified as academic, media, nonprofit, government, or not disclosed. Information describing cancer risk was recorded. The DISCERN instrument measured the quality of content regarding treatment choices. Four standardized tests were used to measure readability. Results: Twenty-one websites were included. The majority of the websites (20/21, 95%) described the cancer risk associated with pancreatic cysts. Nearly half of the websites were written by an academic hospital or organization. The average DISCERN score for all websites was 40.4 (range 26-65.5, maximum 80). Websites received low scores due to lack of references, failure to describe the risks of treatment, or lack of details on how treatment choices affect quality of life. The average readability score was 14.74 (range 5.76-23.85, maximum 19+), indicating a college reading level. There were no significant differences across website affiliation groups. Conclusions: Web-based information for patients with pancreatic cysts is of moderate quality and is written above the reading level of most Americans. Gastroenterological, cancer treatment organizations, and physicians should advocate for improving the available information by providing cancer risk stratification, treatment impact on quality of life, references, and better readability.